Kalkine has a fully transformed New Avatar.

Switch to Old version
1800-272-662
Shopping Cart 0
countryflagAU
Login

Creo Medical Group PLC

Healthcare GB CREO

14.125GBX
0.38(2.73%)

Last update at 2026-03-10T16:23:00Z

Day Range

13.5514.50
LowHigh

52 Week Range

9.2218.50
LowHigh

Fundamentals

  • Previous Close 13.75
  • Market Cap58.26M
  • Volume381598
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-23.30000M
  • Revenue TTM4.60M
  • Revenue Per Share TTM0.01
  • Gross Profit TTM 2.10M
  • Diluted EPS TTM-

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Income before tax -29.00000M -24.50000M -30.97700M -30.33900M -23.46180M
Minority interest - - - - -
Net income -28.70000M -21.70000M -26.93600M -24.59500M -20.31573M
Selling general administrative 30.30M 40.50M 43.93M 41.54M 27.12M
Selling and marketing expenses - 15.20M - - -
Gross profit 1.90M 15.30M 13.12M 11.59M 4.03M
Reconciled depreciation 2.50M 3.40M 3.11M 2.56M 1.60M
Ebit -28.60000M -24.10000M -30.75600M -29.90700M -23.03717M
Ebitda -26.10000M -20.70000M -27.57800M -27.31400M -21.24561M
Depreciation and amortization 2.50M 3.40M 3.18M 2.59M 1.79M
Non operating income net other - - - - -
Operating income -28.80000M -24.80000M -30.75600M -29.90700M -23.03717M
Other operating expenses 32.80M 55.60M 57.92M 55.07M 32.47M
Interest expense 0.40M 0.40M 0.29M 0.46M 0.17M
Tax provision -1.20000M -2.80000M -4.04100M -5.74400M -3.14608M
Interest income 0.20M 0.70M 0.07M 0.03M 0.18M
Net interest income -0.20000M 0.30M -0.22100M -0.33200M 0.00522M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -1.20000M -2.80000M -4.04100M -5.74400M -3.14608M
Total revenue 4.00M 30.80M 27.17M 25.16M 9.43M
Total operating expenses 30.70M 40.10M 43.88M 41.49M 27.07M
Cost of revenue 2.10M 15.50M 14.05M 13.58M 5.39M
Total other income expense net -0.20000M 0.50M -0.22100M -0.43200M -0.42464M
Discontinued operations - - - - -
Net income from continuing ops -27.80000M -21.70000M -26.93600M -24.59500M -20.31573M
Net income applicable to common shares - - - -24.59500M -20.31573M
Preferred stock and other adjustments - - - - -
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Total assets 65.00M 76.60M 75.34M 100.61M 93.50M
Intangible assets 0.50M 7.10M 8.08M 8.69M 10.27M
Earning assets - - - - -
Other current assets 43.70M 3.40M - 9.13M 8.61M
Total liab 22.60M 16.80M 25.93M 27.29M 30.70M
Total stockholder equity 42.40M 59.80M 49.40M 73.32M 62.81M
Deferred long term liab - - - 0.36M 0.49M
Other current liab 16.90M 3.60M 2.87M 4.22M 4.07M
Common stock 0.40M 0.40M 0.18M 0.18M 0.16M
Capital stock 0.40M 0.40M 0.18M 0.18M 0.16M
Retained earnings -173.10000M -144.40000M -122.69600M -95.76000M -71.16491M
Other liab - - - 2.38M 2.32M
Good will 0.00000M 19.10M 19.56M 18.56M 18.26M
Other assets - 0.00000M - 2.21M 1.08M
Cash 8.70M 3.00M 13.10M 43.53M 45.09M
Cash and equivalents - - - - -
Total current liabilities 20.50M 9.90M 17.48M 19.74M 21.84M
Current deferred revenue - -0.20000M - 0.21M 2.00M
Net debt -4.30000M 5.30M -1.41400M -32.97800M -32.73689M
Short term debt 2.40M 3.10M 5.62M 5.38M 5.81M
Short long term debt 2.20M 2.50M 1.59M 4.71M 5.19M
Short long term debt total 4.40M 8.30M 11.68M 10.56M 12.35M
Other stockholder equity 192.00M 180.90M 171.92M 168.90M 133.81M
Property plant equipment - - - 8.60M 3.38M
Total current assets 56.40M 37.90M 33.69M 61.17M 60.51M
Long term investments - - - - -
Net tangible assets - - - 46.42M 34.77M
Short term investments - 15.50M - - -
Net receivables 1.30M 7.90M 6.76M 8.76M 8.37M
Long term debt 1.90M 4.40M 4.89M 3.79M 5.16M
Inventory 2.70M 8.10M 9.32M 8.50M 6.81M
Accounts payable 0.90M 2.70M 9.00M 9.92M 9.96M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 23.10M 22.90M - - -
Additional paid in capital - - - - -
Common stock total equity - - - - 0.16M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.10M 0.20M 2.27M 0.15M 0.61M
Deferred long term asset charges - - - - -
Non current assets total 8.60M 38.70M 41.65M 39.44M 32.99M
Capital lease obligations 0.30M 1.40M 1.73M 2.06M 2.01M
Long term debt total - - - - -
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Investments 15.30M -18.30000M -5.96100M -7.84300M -20.96760M
Change to liabilities - - - 1.88M 1.69M
Total cashflows from investing activities 15.30M -18.30000M - -7.84300M -20.96760M
Net borrowings 5.80M -1.20000M - -2.21500M 1.17M
Total cash from financing activities 16.20M 29.80M 0.45M 31.99M 1.33M
Change to operating activities - - - - -
Net income -27.80000M -21.70000M -26.93600M -24.59500M -20.31573M
Change in cash 9.30M -10.10000M -30.43700M -1.55800M -35.95690M
Begin period cash flow 3.00M 13.10M 43.53M 45.09M 81.05M
End period cash flow 12.30M 3.00M 13.10M 43.53M 45.09M
Total cash from operating activities -22.20000M -21.60000M -24.98400M -26.01100M -16.27891M
Issuance of capital stock 11.10M 31.70M 0.00000M 34.21M 0.16M
Depreciation 2.50M 3.40M 3.11M 2.56M 1.60M
Other cashflows from investing activities 15.60M -14.70000M - 0.03M 0.20M
Dividends paid - - - - -
Change to inventory 0.70M -0.40000M -0.34800M -2.96700M 0.77M
Change to account receivables -1.00000M -1.40000M - -3.17000M -0.39401M
Sale purchase of stock - - - - 0.16M
Other cashflows from financing activities -0.70000M -0.70000M 2.02M -0.37100M 1.66M
Change to netincome - - - 0.28M 0.38M
Capital expenditures 0.40M 1.20M 3.27M 6.12M 0.58M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -0.10000M -5.50000M -2.75000M -4.26200M 2.06M
Stock based compensation 1.50M 1.20M 1.40M 2.56M 0.73M
Other non cash items 1.70M 1.00M 0.19M 0.43M -0.02410M
Free cash flow -22.60000M -22.80000M -28.25800M -32.13300M -16.85514M

Peer Comparison

Sector: Healthcare Industry: Medical Devices

Company Change (GBX) Price (GBX) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
CREO
Creo Medical Group PLC		 0.38 2.73% 14.12 - - 12.67 1.00 9.68 12.73
SN
Smith & Nephew PLC		 - -% 1232.00 53.70 14.27 1.75 2.26 2.21 13.21
NIOX
NIOX Group PLC		 0.60 0.97% 62.60 32.00 20.75 7.92 3.40 7.31 28.40
EKF
EKF Diagnostics Holdings Plc		 - -% 26.70 - - 2.40 2.09 2.25 -19.3996
AOTI
AOTI Inc		 - -% 34.00 18.25 8.33 0.67 3.21 1.00 8.46

Reports Covered

Stock Research & News

View All

Profile

Creo Medical Group PLC, through its subsidiaries, engages in the research, development, manufacture, and sale of medical devices and instruments for clinics and hospitals in the United Kingdom. It develps CROMA, an energy platform that combines bipolar radiofrequency for precise localized cutting and microwave energy for controlled coagulation, to provide physicians with controllable devices delivered through an endoscope. The company also offers Speedboat Inject, an energy multimodal instrument for endoscopy; MicroBlate Fine, a microwave needle ablation device; MicroBlate Flex, a microwave ablation device designed for soft tissue ablation; and SpydrBlade Flex, a multi-modal endoscopic scissor-type device. In addition, it provides endotherapy accessories comprising injection needles, haemostatic clips, snares, and forceps, as well as other products for gastroenterology, pulmonology, and urology. Further, the company offers products for diagnostic, therapeutic, and hygiene purposes. Creo Medical Group PLC was founded in 2003 and is headquartered in Chepstow, the United Kingdom.

Creo Medical Group PLC

Creo House, Chepstow, United Kingdom, NP16 5UH

Key Executives

Name Title Year Born
Mr. Craig Jonathan Gulliford CEO & Exec. Director 1971
Prof. Christopher Paul Hancock Founder, CTO & Exec. Director 1968
Mr. Richard John Rees ACA CFO, Company Sec. & Exec. Director 1977
Mr. David Gerard Woods Chief Commercial Officer & Exec. Director 1966
Mr. Phil Hales Sales & Marketing Director NA
Mr. Craig Jonathan Gulliford CEO & Executive Director 1970
Prof. Christopher Paul Hancock Founder & CTO 1967
Mr. Richard John Rees ACA CFO & Executive Director 1976
Mr. David Gerard Woods Chief Commercial Officer 1965
Mr. Richard Gary Craven Secretary NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.